Oldfield Partners LLP lifted its holdings in Pfizer Inc. (NYSE:PFE) by 33.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 109,850 shares of the biopharmaceutical company’s stock after purchasing an additional 27,300 shares during the quarter. Pfizer accounts for approximately 0.3% of Oldfield Partners LLP’s holdings, making the stock its 15th largest position. Oldfield Partners LLP’s holdings in Pfizer were worth $3,979,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in PFE. Mckinley Capital Management LLC Delaware bought a new position in Pfizer during the second quarter valued at about $103,000. Herndon Capital Management LLC bought a new position in Pfizer during the second quarter valued at about $120,000. Americafirst Capital Management LLC bought a new position in Pfizer during the third quarter valued at about $127,000. Oak Point Wealth Management bought a new position in Pfizer during the fourth quarter valued at about $165,000. Finally, Lipe & Dalton lifted its holdings in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 300 shares during the last quarter. 71.41% of the stock is owned by institutional investors.
Shares of Pfizer Inc. (PFE) opened at $36.78 on Friday. The stock has a market capitalization of $218,950.00, a PE ratio of 21.02, a P/E/G ratio of 2.06 and a beta of 0.91. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. Pfizer Inc. has a one year low of $31.67 and a one year high of $39.43.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business’s revenue for the quarter was up .6% on a year-over-year basis. During the same period in the prior year, the business earned $0.47 EPS. analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer declared that its Board of Directors has authorized a stock repurchase program on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were paid a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.70%. The ex-dividend date of this dividend was Thursday, February 1st. Pfizer’s dividend payout ratio is currently 77.71%.
In other Pfizer news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares of the company’s stock, valued at approximately $1,374,505.21. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director W Don Cornwell sold 1,758 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total value of $64,676.82. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Over the last three months, insiders sold 248,037 shares of company stock valued at $9,064,785. Company insiders own 0.06% of the company’s stock.
Several equities research analysts have recently commented on PFE shares. SunTrust Banks reaffirmed a “hold” rating and set a $40.00 target price (up from $33.00) on shares of Pfizer in a report on Monday, January 29th. Jefferies Group set a $39.00 target price on Pfizer and gave the company a “hold” rating in a report on Monday, February 26th. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price for the company. in a report on Monday, January 15th. Bank of America set a $40.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Finally, BMO Capital Markets set a $43.00 target price on Pfizer and gave the company a “buy” rating in a report on Monday, February 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average price target of $39.40.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/18/pfizer-inc-pfe-stake-lifted-by-oldfield-partners-llp.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.